A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

OBJECTIVES: The epidermal growth factor receptor (EGFR) is a validated target in head and neck squamous cell carcinoma (HNSCC). In recurrent and/or metastatic (R/M) HNSCC, resistance to anti-EGFR therapy inevitably occurs. Downstream activation of the PI3K/Akt/mTOR pathway is an established resistan...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bauman, Julie E., Arias-Pulido, Hugo, Lee, Sang-Joon, Fekrazad, M. Houman, Ozawa, Hiroyuki, Fertig, Elana, Howard, Jason, Bishop, Justin, Wang, Hao, Olson, Garth T., Spafford, Michael J., Jones, Dennie V., Chung, Christine H.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3805493/
https://ncbi.nlm.nih.gov/pubmed/23384718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2012.12.016
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires